3:03 PM
Aug 31, 2017
 |  BioCentury  |  Finance

Fund fine-tuning

How Swiss VC BioMedPartners is tweaking its third life sciences fund

BioMedPartners is fine-tuning its strategy for its third fund to focus more on therapeutics investments, where the firm has seen most of its biggest returns.

The Swiss VC told BioCentury BioMedInvest III has reached an interim close of about CHF100 million ($104.7 million), following a first close of CHF75 million ($75.1 million) in February. The firm is targeting a final close next February of CHF120-CHF150 million ($125.7-$157.2 million).

“Our nicest exits consistently were pharma or...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >